Compare BUUU & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BUUU | CLNN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.4M | 120.6M |
| IPO Year | 2025 | N/A |
| Metric | BUUU | CLNN |
|---|---|---|
| Price | $7.98 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 44.6K | ★ 305.1K |
| Earning Date | 12-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $6,328,425.00 | $214,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $87.58 |
| P/E Ratio | $150.87 | ★ N/A |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $3.67 | $2.28 |
| 52 Week High | $9.50 | $13.50 |
| Indicator | BUUU | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 32.08 |
| Support Level | N/A | $8.90 |
| Resistance Level | N/A | $9.92 |
| Average True Range (ATR) | 0.00 | 1.03 |
| MACD | 0.00 | -0.40 |
| Stochastic Oscillator | 0.00 | 2.12 |
BUUU Group Ltd provides comprehensive meetings, incentives, conferences, and exhibitions (MICE) solutions focused on event management and stage production. Its event management team offers creative planning, project management, and on-site supervision for a wide range of cultural, artistic, recreational, and corporate events, working closely with clients and partners. The stage production team creates immersive event experiences by managing lighting, audio-visual systems, stage performance elements, and venue decorations, overseeing the entire production process. Event management generates the majority of revenue.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.